Emicizumab

Drug Profile

Emicizumab

Alternative Names: ACE910; Anti-factor IXa x anti-factor X humanized bispecific antibody; CH5534262; RG 6013; RO 5534262

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antihaemorrhagics; Bispecific antibodies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 15 Jun 2017 Roche plans the phase IIIb STASEY trial for Haemophilia A (In children, In adolescents, In adults, In the elderly, Treatment-experienced) in Australia, Belgium, Canada, Denmark, Finland, Germany, Guatemala, Hungary, Mexico, the Netherlands, Panama, Poland, Portugal, Russia, Saudi Arabia, Switzerland and United Kingdom (SC) (NCT03191799)
  • 19 May 2017 Roche plans the regulatory submission for emicizumab for the treatment of Haemophilia A in 2017 (Roche pipeline, October 2014).
  • 12 May 2017 Genentech initiates enrolment in an expanded access program for Haemophilia A (In adolescents, In adults, In children) in USA (NCT03154437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top